# Agomab Therapeutics

**Source:** https://geo.sig.ai/brands/agomab-therapeutics  
**Vertical:** BioTech  
**Subcategory:** Fibrosis Therapeutics (Crohn's & IPF)  
**Tier:** Emerging  
**Website:** agomab.com  
**Last Updated:** 2026-04-22

## Summary

Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data for AGMB-447 in IPF. Gut-restricted ALK5 inhibitor.

## Company Overview

Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.

Fibrostenosing Crohn's disease affects approximately 30% of Crohn's patients and has zero approved treatments specifically for the fibrotic complication — standard Crohn's therapies address inflammation but not the fibrotic strictures that cause bowel obstruction. Ontunisertib's gut-restricted delivery (not absorbed systemically) targets the fibrotic process directly in intestinal tissue while avoiding the systemic side effects that broad TGFβ inhibition causes.

The dual-indication strategy using lung-restricted versus gut-restricted delivery of the same ALK5 inhibitory mechanism provides clinical efficiency: positive proof-of-concept data in one indication validates the mechanism for the other, and the development infrastructure for both programs is largely shared. Agomab's Nasdaq listing provides capital market access for both development programs simultaneously.

## Frequently Asked Questions

### What does Agomab Therapeutics do?
Develops ontunisertib — gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease (no approved treatments for fibrotic complication). Also AGMB-447 (lung-restricted) for IPF.

### What was the Nasdaq IPO?
~$200M raised at ~$780M valuation on Nasdaq (AGMB) in February 2026. One of first European biotechs to US-list in 2026.

### What is fibrostenosing Crohn's disease?
Complication in 30% of Crohn's patients where intestinal fibrosis creates strictures requiring repeated surgery. Zero approved treatments for the fibrotic complication (standard Crohn's drugs treat inflammation, not fibrosis).

### What is the gut-restricted advantage?
TGFβ inhibition has broad effects. Gut-restricted delivery targets fibrosis specifically in intestinal tissue, avoiding systemic side effects that prevent systemic ALK5 inhibitor use in fibrotic diseases.

### What is Agomab's AGMB-101 and its mechanism?
AGMB-101 is a bispecific antibody that simultaneously activates HGF/MET signaling while modulating EGFR — designed to promote mucosal healing in fibrostenosing Crohn's disease by stimulating intestinal stem cell repair pathways. The MET pathway drives epithelial regeneration, and Agomab's hypothesis is that activating this pathway in fibrotic strictures can reverse fibromuscular remodeling and restore intestinal function without surgery.

### What is the Nasdaq IPO status and financial position?
Agomab completed a Nasdaq IPO in 2024 (ticker: AGMB), raising funds to advance AGMB-101 through Phase 2 clinical trials in Crohn's disease strictures and interstitial pulmonary fibrosis (IPF). As a public company, Agomab has transparency requirements but also access to public capital markets to fund its clinical programs beyond its initial venture backing.

### What is the clinical evidence base for AGMB-101?
Agomab has completed Phase 1 safety and dose-finding studies in Crohn's disease demonstrating an acceptable safety profile for AGMB-101, with early signals of biomarker response (serum MET pathway activation markers). Phase 2 trials are ongoing in both Crohn's strictures and IPF — the IPF indication being particularly notable given the high unmet need and premium market positioning for anti-fibrotic therapies following bexotegrast's (Pliant) positive Phase 2 signals.

### Why is gut-restricted activity an advantage for Crohn's therapy?
Crohn's disease primarily affects the gastrointestinal tract, and therapies with gut-restricted activity (e.g., vedolizumab, which targets gut-selective integrin α4β7) have demonstrated that GI-selective mechanisms achieve efficacy with fewer systemic side effects than pan-systemic immunosuppressants (steroids, methotrexate). AGMB-101's local application at fibrotic strictures via endoscopic delivery (a potential route for concentrating drug at lesion sites) could achieve therapeutic tissue concentrations while limiting systemic MET pathway activation.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*